Orum Therapeutics, a private biotechnology company pioneering the development of tumour-directed targeted protein degraders (TPDs), announced that the first patient has been dosed with ORM-5029 in a phase 1 clinical trial for patients with HER2-expressing advanced solid tumours.
ORM-5029 is one of two lead programs from the company
